glp-1 market share of RAs in 2016 and 2017 GLP-1 Analogues Market Report, Growth

Skipping this careful titration process through microdosing can prevent patients from reaching the therapeutic levels needed for effective treatment

The data indicate that dysregulated serotonin metabolism may be a critical role in PBH [33]

Current limited evidence does not suggest GLP-1 agonists worsen Crohn's disease, but their gastrointestinal side effects may complicate symptom monitoring

16 As a secondary outcome, the trial demonstrated a 32% reduction in renal events with efpeglenatide (HR 0.68

accessed August 25, 2025)

This therapeutic effect appears to enhance the anti-inflammatory properties of these medications and may contribute to their broader metabolic benefits beyond weight loss